Smith & Nephew PLC ORD USD0.20
Smith & Nephew PLC ORD USD0.20/ GB0009223206 /
SN/
|
18/10/2024 17:59:32
|
Diferencia
+5.7040
|
Volumen |
Bid18:30:00 |
Ask18:30:00 |
Capitalización de mecado |
Dividendo A. |
P/E Ratio |
|
1,128.0000GBX
|
+0.51%
|
664,418
Volumen de negocios(GBP): 7.43 millones |
-Volumen de oferta: - |
1,200.0000Tamaño/ Volumen/ Formato de Ask: 2,643 |
9.88 mil millonesGBP |
- |
- |
Descripción de negocio
Smith & Nephew plc is a global medical technology business. The company has two reportable business segments: Advanced Surgical Devices (Orthopaedic Reconstruction, Trauma & Extremities, Sports Medicine and Arthroscopy Enabling Technologies) and Advanced Wound Management. Smith & Nephew has a track record of bringing innovative new products to market that provide better clinical outcomes for patients and save costs for healthcare providers. The company has distribution channels, purchasing agents and buying entities in over 100 countries worldwide. Smith & Nephew plc is headquartered in London, UK.
Consejo de gestión & Consejo de supervisión
| CEO |
| Deepak Nath |
| Consejo de gestión |
| John Rogers, Paul Connolly, Phil Cowdy, Mizanu Kebede, Elga Lohler, Vasant Padmanabhan, Alison Parkes, Helen Barraclough, Scott Schaffner, Rohit Kashyap, Craig Gaffin |
| Consejo de supervisión |
| Rupert Soames, Deepak Nath, Marc Owen, Jo Hallas, John Ma, Angie Risley, Bob White, Katarzyna Mazur-Hofsaess, John Rogers, Simon Lowth, Jez Maiden |
Datos de la empresa
| Nombre: |
Smith & Nephew plc |
| Dirección: |
Building 5, Croxley Park Hatters Lane Watford,Hertfordshire WD18 8YE UK |
| Teléfono: |
+44-1923-477-100 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.smith-nephew.com/ |
| Industria: |
Healthcare |
| Sector: |
Medical Products |
| Subsector: |
Advanced Medical Devices |
| Fin del año financiero: |
31/12 |
| Acciones de libre circulación: |
- |
| Fecha de OPI: |
- |
Calendario de la empresa
|
CW 44 | 31/10/2024
Interim Report 3rd Quarter/9 Months
|
|
CW 45 | 08/11/2024
Dividend Payment
|
|
CW 9 | 25/02/2025
4th Quarter/Annual Report
|
